Tractus Corporation

Tractus Corporation develops innovative medical imaging solutions, focusing on enhancing breast cancer screening through advanced ultrasound technology and systems integration. Tractus Corporation specializes in medical imaging solutions, particularly with its Tractus Breast Mapper® and Reviewer and Image Recording System. Headquartered in Danville, US, the company has undergone strategic developments to enhance its product offerings. Notably, in April 2013, Tractus Corporation raised an undisclosed amount in venture funding from Green Park & Golf Ventures, reinforcing its commitment to advancing breast cancer detection.

The company operates under the leadership of CEOs Brad Hummel and Vitaly Begar. Tractus Corporation specializes in medical imaging solutions, primarily offering the Tractus Breast Mapper® and its Reviewer and Image Recording System. These FDA 510(k) cleared devices provide comprehensive documentation of the entire breast, including the axilla and inframammary fold, utilizing existing ultrasound systems to enhance breast cancer screening. The Tractus Breast Mapper® is designed to address the challenges posed by dense breast tissue, which can hinder traditional mammography's effectiveness.

By integrating seamlessly with common ultrasound equipment, the system aims to improve cancer detection rates, particularly in women with dense breast tissue, thereby offering a more holistic approach to breast health. The primary end users include healthcare providers, radiologists, and medical facilities in North America and various international markets, where breast cancer screening is an essential component of women's healthcare. Tractus Corporation generates revenue through direct sales of its flagship products, the Tractus Breast Mapper® and the Reviewer and Image Recording System, to healthcare institutions and facilities engaged in breast cancer detection and treatment. The transactions typically occur on a B2B basis, where medical facilities purchase these advanced imaging systems for integration into their existing diagnostic workflows.

The pricing structure may vary based on the specific configurations and services required by clients, ensuring that institutions are equipped to enhance their screening capabilities. Additionally, the company may engage in partnerships with medical providers and research institutions, facilitating the adoption of its technology and contributing to ongoing clinical studies that validate the effectiveness of its products. Tractus Corporation plans to launch new iterations of its imaging systems to further enhance breast cancer detection capabilities. The company is also targeting expansion into international markets, specifically aiming for growth in Europe and Asia by the end of 2025.

The funding raised in April 2013 is expected to support the development of these new products and market entry strategies, helping the company to solidify its presence in critical regions for breast health diagnostics.